$SRDX (SurModics, Inc.)

$SRDX {{ '2016-01-11T16:08:15+0000' | timeago}} • Announcement

As a result of the NorMedix transaction, $SRDX lifted FY16 revenue guidance to range of $62-66MM from previous forecast range of $60-64MM. For 2016, $SRDX lowered its EPS outlook to range of $0.30-0.35 from prior forecast of $0.38-0.43. The transaction is not expected to impact non-GAAP earnings guidance of $0.66-0.75 per share.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$HRC {{ '2017-07-19T14:11:03+0000' | timeago}} • Announcement

$HRC declared a dividend of $0.18 per share for 4Q17 payable on September 29, 2017, to shareholders of record as of September 15, 2017. The indicated annual dividend rate is $0.72 per share.

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$VRTX {{ '2017-07-13T12:31:35+0000' | timeago}} • Announcement

$VRTX announced that the Italian Medicines Agency has agreed to reimburse ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation. Effective immediately, hundreds of eligible patients in Italy will have access to this medicine.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$VRX {{ '2017-07-10T13:27:06+0000' | timeago}} • Announcement

$VRX pays down $811MM of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC. The company has now reduced its debt by more than $4.3Bil since the end of 1Q16. $VRX still expects to pay down $5Bil in debt from divestiture proceeds and free cash flow within 18 months of August 2016.

$ABT {{ '2017-06-29T17:53:11+0000' | timeago}} • Announcement

$ABT announced the Health Canada license of its FreeStyle Libre Flash Glucose Monitoring System, a glucose sensing technology for adults with diabetes. This system eliminates the need for routine finger sticks or finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.

$WBA {{ '2017-06-29T14:01:47+0000' | timeago}} • Announcement

$WBA agreed to buy 2,186 stores, three distribution centers and related inventory from $RAD. $WBA expects the new transaction to be modestly accretive to its adjusted EPS in the first full year after the initial closing of the new transaction, and expects to realize synergies from the new transaction in excess of $400MM.

$WBA {{ '2017-06-29T14:01:00+0000' | timeago}} • Announcement

$WBA agreed to buy 2,186 stores, three distribution centers and related inventory from $RAD. This new agreement replaces the previous merger agreement with Rite Aid, announced in October 2015 and amended in January 2017. The initial closing of the new transaction is expected to occur within the next six months.

$WBA {{ '2017-06-29T14:00:00+0000' | timeago}} • Announcement

$WBA agreed to buy 2,186 stores, three distribution centers and related inventory from $RAD. The consideration for the transaction will be $5.175Bil in cash, the assumption by $WBA of the related real estate leases and the grant of an option to $RAD to become a member of $WBA's group purchasing organization, Walgreens Boots Alliance Development.

$WBA {{ '2017-06-29T13:35:36+0000' | timeago}} • Webcast

$WBA said that on the $RAD agreement, while the company is assuming a real-estate obligation, it is not assuming any debt. Additionally, $WBA is expecting the deal to give significant cash tax benefit, as it tax amortizes the intangible assets it acquires from $RAD.

$RAD {{ '2017-06-29T12:19:47+0000' | timeago}} • Announcement

In 1Q18, $RAD opened one store, relocated four, remodeled 67 and expanded one store, bringing the total number of wellness stores chainwide to 2,482. The company closed 14 stores, resulting in a total store count of 4,523 at the end of the first quarter.

$RAD {{ '2017-06-29T12:18:00+0000' | timeago}} • Announcement

Drugstore chain $RAD posted revenue of $7.8Bil in 1Q18, a decrease of 4.9%, as same store sales slid 3.9% YoY. Net loss widened to $75.3MM or $0.07 per share, compared to last year’s $4.6MM or $0.00 per share, hurt by lower pharmacy gross profit. Adjusted EBITDA was $192.6MM compared to $286MM in the year-over period.

$RAD {{ '2017-06-29T12:09:28+0000' | timeago}} • Announcement

$RAD and $WBA announced that the latter will not buy the former as initially announced. Instead of the previously announced deal that was severely scrutinized by the Federal Trade Commission, $WBA will instead buy 2,186 Rite Aid Stores and Related Assets for $5.17Bil. Rite Aid will receive $325MM from $WBA as termination fee.

$WBA {{ '2017-06-29T11:32:22+0000' | timeago}} • Announcement

$WBA, which reached an agreement with $RAD worth $5.17Bil today, reported a modest 5% increase in earnings for 3Q17 upon strategic partnerships that brought more patients to its pharmacies. Both sales and earnings inched up, with sales scaling up 2.1% to $30.1Bil, while earnings rose to $1,162MM. Adjusted earnings spiked 12.7% to $1.33 per share.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
SRDX (SurModics, Inc.)
Thursday, April 27 2017 - 12:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, February 28 2017 - 10:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, February 28 2017 - 1:00pm
GMED (Globus Medical, Inc.)
Monday, February 27 2017 - 10:30pm

AlphaGraphics you may like